126 related articles for article (PubMed ID: 27748547)
1. Gold Nanocarriers for Macrophage-Targeted Therapy of Human Immunodeficiency Virus.
Zazo H; Colino CI; Warzecha KT; Hoss M; Gbureck U; Trautwein C; Tacke F; Lanao JM; Bartneck M
Macromol Biosci; 2017 Mar; 17(3):. PubMed ID: 27748547
[TBL] [Abstract][Full Text] [Related]
2. Colloidal gold-loaded, biodegradable, polymer-based stavudine nanoparticle uptake by macrophages: an in vitro study.
Basu S; Mukherjee B; Chowdhury SR; Paul P; Choudhury R; Kumar A; Mondal L; Hossain CM; Maji R
Int J Nanomedicine; 2012; 7():6049-61. PubMed ID: 23271908
[TBL] [Abstract][Full Text] [Related]
3. Macrophage targeted nanocarrier delivery systems in HIV therapeutics.
Khan T; Mayuresh Patkar M; Momin M; Omri A
Expert Opin Drug Deliv; 2020 Jul; 17(7):903-918. PubMed ID: 32347124
[TBL] [Abstract][Full Text] [Related]
4. Ga(III) Nanoparticles Inhibit Growth of both Mycobacterium tuberculosis and HIV and Release of Interleukin-6 (IL-6) and IL-8 in Coinfected Macrophages.
Choi SR; Britigan BE; Narayanasamy P
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167548
[TBL] [Abstract][Full Text] [Related]
5. Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection.
Gross E; Amella CA; Pompucci L; Franchin G; Sherry B; Schmidtmayerova H
J Leukoc Biol; 2003 Nov; 74(5):781-90. PubMed ID: 12960233
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-Based ARV Drug Combinations for Synergistic Inhibition of Cell-Free and Cell-Cell HIV Transmission.
Jiang Y; Cao S; Bright DK; Bever AM; Blakney AK; Suydam IT; Woodrow KA
Mol Pharm; 2015 Dec; 12(12):4363-74. PubMed ID: 26529558
[TBL] [Abstract][Full Text] [Related]
7. Stavudine-loaded mannosylated liposomes: in-vitro anti-HIV-I activity, tissue distribution and pharmacokinetics.
Garg M; Asthana A; Agashe HB; Agrawal GP; Jain NK
J Pharm Pharmacol; 2006 May; 58(5):605-16. PubMed ID: 16640829
[TBL] [Abstract][Full Text] [Related]
8. Induction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral Therapy.
Gill AJ; Kovacsics CE; Vance PJ; Collman RG; Kolson DL
J Virol; 2015 Oct; 89(20):10656-67. PubMed ID: 26269184
[TBL] [Abstract][Full Text] [Related]
9. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
[TBL] [Abstract][Full Text] [Related]
10. Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.
Narayanasamy P; Switzer BL; Britigan BE
Sci Rep; 2015 Mar; 5():8824. PubMed ID: 25744727
[TBL] [Abstract][Full Text] [Related]
11. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.
Roy U; Ding H; Pilakka-Kanthikeel S; Raymond AD; Atluri V; Yndart A; Kaftanovskaya EM; Batrakova E; Agudelo M; Nair M
Int J Nanomedicine; 2015; 10():5819-35. PubMed ID: 26425084
[TBL] [Abstract][Full Text] [Related]
13. Gold nanoparticles to improve HIV drug delivery.
Garrido C; Simpson CA; Dahl NP; Bresee J; Whitehead DC; Lindsey EA; Harris TL; Smith CA; Carter CJ; Feldheim DL; Melander C; Margolis DM
Future Med Chem; 2015; 7(9):1097-107. PubMed ID: 26132521
[TBL] [Abstract][Full Text] [Related]
14. Stavudine loaded gelatin liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic evaluation.
Nayak D; Boxi A; Ashe S; Thathapudi NC; Nayak B
Mater Sci Eng C Mater Biol Appl; 2017 Apr; 73():406-416. PubMed ID: 28183626
[TBL] [Abstract][Full Text] [Related]
15. Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection.
Fulcher JA; Tamshen K; Wollenberg AL; Kickhoefer VA; Mrazek J; Elliott J; Ibarrondo FJ; Anton PA; Rome LH; Maynard HD; Deming T; Yang OO
Bioconjug Chem; 2019 Aug; 30(8):2216-2227. PubMed ID: 31265254
[TBL] [Abstract][Full Text] [Related]
16. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Molina JM; Chêuc G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM;
Antivir Ther; 1999; 4 Suppl 3():71-4. PubMed ID: 16021874
[TBL] [Abstract][Full Text] [Related]
17. Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte-derived macrophages: the importance of HIV-1 envelope V1V2 region.
Jobe O; Trinh HV; Kim J; Alsalmi W; Tovanabutra S; Ehrenberg PK; Peachman KK; Gao G; Thomas R; Kim JH; Michael NL; Alving CR; Rao VB; Rao M
J Leukoc Biol; 2016 Jun; 99(6):1089-106. PubMed ID: 26667473
[TBL] [Abstract][Full Text] [Related]
18. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
[TBL] [Abstract][Full Text] [Related]
19. Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.
Mateo MG; Gutierrez Mdel M; Vidal F; Domingo P
Expert Opin Drug Saf; 2012 May; 11(3):473-85. PubMed ID: 22468613
[TBL] [Abstract][Full Text] [Related]
20. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy.
Hauber I; Bevec D; Heukeshoven J; Krätzer F; Horn F; Choidas A; Harrer T; Hauber J
J Clin Invest; 2005 Jan; 115(1):76-85. PubMed ID: 15630446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
